Alyssa Siefert Jarvi, Ph.D., is a biomedical engineer, innovation strategist, and venture ecosystem leader whose career has been defined by her ability to translate complex scientific breakthroughs into meaningful, real-world impact. With more than 15 years of professional experience spanning academia, venture capital, and early-stage company development, she has built a reputation as a connector—someone who brings together people, ideas, and resources to solve some of healthcare’s most pressing challenges. Her work sits at the intersection of science, business, and communication, where she helps organizations unlock the full value of innovation.
Dr. Jarvi began her journey with a strong foundation in engineering, earning her Bachelor of Science in Biomedical and Chemical Engineering from Carnegie Mellon University. She went on to Yale University, where she completed her Master of Science, Master of Philosophy, and Ph.D. in Biomedical Engineering with distinction. Her doctoral research focused on biomimetic nanosystems targeting immune cells, contributing to advancements in immunotherapeutics and leading to her role as a co-inventor on a foundational lipid nanoparticle patent. These early experiences shaped her deep technical expertise and her appreciation for the complexity of translating scientific discovery into practical application.
During her time at Yale, Dr. Jarvi distinguished herself not only as a researcher but also as a leader and educator. She taught multiple courses in biomedical engineering and medical device innovation, mentoring students and fostering interdisciplinary collaboration. Her commitment to education extended beyond the classroom, as she played a pivotal role in building programs that connected clinicians, engineers, and entrepreneurs. This early exposure to cross-functional teamwork laid the groundwork for her future career in innovation and commercialization.
Following her doctoral and postdoctoral work, Dr. Jarvi transitioned into roles that emphasized the translation of science into actionable outcomes. As Engineering Director at the Yale Center for Biomedical Innovation and Technology, she led initiatives that accelerated healthcare innovation by connecting academic research with industry needs. She organized clinical immersion programs, guided multidisciplinary teams, and mentored ventures navigating technical, regulatory, and business challenges. Her leadership contributed to the advancement of numerous projects and helped shape a model for effective biomedical innovation.
Dr. Jarvi’s career took a strategic turn when she entered the venture capital space with Foresite Capital, where she spent over five years in roles of increasing responsibility. As a Senior Associate in Investment Communications, she played a critical role in due diligence, analyzing clinical data, and synthesizing competitive intelligence to inform investment decisions. She also became a trusted voice in crafting investor narratives, translating highly technical concepts into clear, compelling stories that resonated with stakeholders. Her ability to bridge scientific rigor with strategic communication proved invaluable in supporting portfolio companies and driving investment outcomes.
In parallel with her work in venture capital, Dr. Jarvi expanded her influence as a consultant, writer, and educator. Through her independent ventures, including ASJ Explorations LLC, she has advised biotech, pharmaceutical, and medtech companies on strategy, content development, and commercialization. Her writing has reached hundreds of thousands of readers, reflecting her talent for making complex scientific topics accessible to broad audiences. This combination of technical depth and communication expertise has become a hallmark of her professional identity.
Currently serving as an Entrepreneur in Residence at Yale Ventures, Dr. Jarvi continues to shape the next generation of healthcare innovation. In this role, she supports the development and commercialization of university-based technologies, guiding founders and researchers as they navigate the path from discovery to market. Her work reinforces her commitment to fostering innovation ecosystems that drive both patient impact and economic value.
Beyond her professional achievements, Dr. Jarvi is deeply committed to community building and mentorship. She is the founder of The River Valley Collective, a nonprofit organization dedicated to fostering connection and education among families. Her leadership extends to advisory roles and board service, including her involvement with a small manufacturing business and her previous tenure on the Board of Governors at Westover School. These experiences reflect her belief in the importance of giving back and supporting the growth of others.
Dr. Jarvi’s career is distinguished by her unique ability to identify and address a critical gap in the healthcare industry: the disconnect between scientific innovation and practical implementation. She has witnessed firsthand the challenges that prevent promising technologies from reaching patients and has dedicated her career to bridging that divide. By aligning scientific, clinical, and business perspectives, she helps organizations develop strategies that maximize both impact and return on investment.
Her leadership style is rooted in curiosity, collaboration, and a relentless drive to learn. She thrives in environments that require coordination across disciplines and is known for her ability to bring clarity to complex problems. Whether working with early-stage startups or established organizations, she approaches each challenge with a combination of analytical rigor and creative thinking.
As she looks toward board service, Dr. Jarvi brings a wealth of experience, a strategic mindset, and a passion for advancing healthcare innovation. She is particularly well-suited to organizations seeking guidance on commercialization, investor communication, and the translation of complex technologies into scalable solutions. Her perspective is informed by years of experience across the full lifecycle of innovation, from discovery to deployment.
Ultimately, Alyssa Siefert Jarvi is driven by a mission to ensure that scientific breakthroughs do not remain confined to the lab but are transformed into solutions that improve lives. Her career reflects a deep commitment to impact, a dedication to excellence, and a belief in the power of connection to drive meaningful change.
Character:
Alyssa exemplifies integrity and purpose in every aspect of her work, consistently aligning her efforts with a mission to improve patient outcomes and societal well-being. She demonstrates resilience and adaptability, navigating complex and evolving environments with confidence and clarity. Her commitment to mentorship and community building underscores her genuine desire to uplift others and create lasting impact beyond her own achievements.
Knowledge:
He possesses deep technical expertise in biomedical engineering, immunotherapy, and nanotechnology, supported by rigorous academic training and real-world application. She combines this scientific foundation with a strong understanding of venture capital, commercialization, and market dynamics. Her ability to integrate knowledge across disciplines enables her to approach challenges holistically and deliver well-informed, innovative solutions.
Strategic:
Alyssa is a forward-thinking strategist who excels at identifying opportunities where science and business intersect. She has a proven ability to guide organizations through complex decision-making processes, from early-stage development to market positioning. Her strategic insight is grounded in data, experience, and a clear understanding of how to translate innovation into scalable and sustainable success.
Communication:
An exceptional communicator who bridges the gap between technical complexity and audience understanding. She has a talent for crafting compelling narratives that resonate with investors, stakeholders, and diverse audiences. Her ability to translate intricate scientific concepts into clear, actionable insights makes her a valuable leader in both boardrooms and broader innovation ecosystems.
